drugset / Trial / NCT02100852
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic leukemia.
Timeline
- Start
- 2014-03-12
- Primary completion
- 2017-11
- Completion
- 2017-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Umbralisib | Small molecule | — | Oral |
| Background | Chlorambucil | Other / unclassified | — | Oral |
| Background | Obinutuzumab | Monoclonal antibody | — | Intravenous |